Safe and effective are defined as follows: Safety is the condition of presenting a reasonably low risk of harm, injury, or loss when a technology is utilized in the specified indication; and effectiveness is the quality of producing a desired, beneficial effect under the conditions of actual use. The categories for response to a DATTA question are defined as follows: Established—a technology demonstrated and accepted as safe and effective by the practicing medical community; investigational—a technology largely confined to use under research protocol; unacceptable—the riskbenefit ratio is unfavorable; and indeterminate—the evidence is insufficient for a definitive decision, and no consensus exists to date; further study may be warranted.
χ2 Analysis of the responses of the DATTA panelists determined that the frequencies of responses (established, investigational, unacceptable, and indeterminate) differ significantly from those expected due to chance alone for all questions. Construction of the 95% confidence intervals comparing the established category vs the combination of investigational, unacceptable, and indeterminate showed a significant difference between these two groups for all questions. The DATTA panelists believed that continuous subcutaneous insulin infusion is established as both a safe and an effective technique for controlling insulin-dependent diabetes. The panelists did not believe continuous subcutaneous insulin infusion is yet established for preventing or reversing diabetic complications. Seven panelists offered no opinion on questions 1A and 1B; eight panelists had no opinion on questions 2A and 2B and 3A and 3B.
Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr . Diabetes . 1987;;36:523-534.
Routes of insulin delivery and use of mechanical infusion systems . In: Shade DS, Santiago JV, Skyler JS, Rizza RA. Intensive Insulin Therapy . Amsterdam, the Netherlands: Medical Examination Publishing Co Inc; 1983;:113-128.
Gill GN, ed. The endocrine pancreas . In: West JB, ed. Best and Taylor's Physiological Basis of Medical Practice . 11th ed. Baltimore, Md: Williams & Wilkins; 1985;:818-833.
DCCT—Diabetes Control and Complications Trial—Protocol . Washington, DC: US Dept of Health and Human Services, Public Health Service, National Institutes of Health; 1988;.
Parsons JA, Rothwell D, Sharpe JE. A miniature syringe pump for continuous administration of drugs and hormones: The Mill Hill infuser . Lancet . 1977;;1:77-78.
Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia . Br Med J. 1978;;1:204-207.
Pickup JC, Keen H, Parsons JA, Alberti KGMM, Rowe AS. Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics . Lancet . 1979;;1:1255-1257.
Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump . N Engl J Med. 1979;;300:573-578.
Tamborlane WV, Sherwin RS, Genel M, Felig P. Restoration of normal lipid and amino acid metabolism in diabetic patients treated with a portable insulininfusion pump . Lancet . 1979;;1:1258-1261.
Hermansen K, Moller A, Christensen CK, et al. Diurnal plasma profiles of metabolite and hormone concentration in insulin-dependent diabetic patients during conventional insulin treatment and continuous subcutaneous insulin infusion . Acta Endocrinol. 1987;;114:433-439.
Champion MC, Shepherd GAA, Rodger NW, Dupre J. Continuous subcutaneous infusion of insulin in the management of diabetes mellitus . Diabetes . 1980;;29:206-212,
Mecklenburg RS, Benson EA, Benson LW, et al. Long-term metabolic control with insulin pump therapy . N Engl J Med. 1985;;313:465-468.
Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria . N Engl J Med. 1984;;311:365-372.
Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T, and the Steno Study Group. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics . Lancet . 1983;;1:200-204.
Ganda OP. Hormones affecting the secretion and actions of insulin . In: Marble A, Krall L, Bradley RF, Christlieb AR, Soeldner JS, eds. Joslin's Diabetes Mellitus . 12th ed. Philadelphia, Pa: Lea & Febiger; 1985;:158-184.
Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects . J Clin Invest. 1970;;49:837-848.
Reynolds C, Molnar GD, Horwitz DL, et al. Abnormalities of endogenous glucagon and insulin in unstable diabetics . Diabetes . 1977;;26:36-45.
Raskin P, Pietri A, Unger R. Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps . Diabetes . 1979;;28:1033-1035.
Gerich JE, Langlois M, Noacco C, et al. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect . Science . 1973;;182:171-173.
Bergenstal RM, Polonsky KS, Pons G, Jaspan JB, Rubenstein AH. Lack of glucagon response to hypoglycemia in type I diabetics after long-term optimal therapy with a continuous subcutaneous insulin infusion pump . Diabetes . 1983;;32:396-402.
Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes . Ann Intern Med. 1985;;103:184-190.
Johansen K, Hansen AP. Diurnal serum growth hormone levels in poorly and well controlled juvenile diabetics . Diabetes . 1971;;20:239-245.
Tamborlane WV, Sherwin RS, Koivisto VA, Hendler R, Genel M, Felig P. Normalization of the growth hormone and catecholamine response to exercise in juvenile-onset diabetic subjects treated with a portable insulin infusion pump . Diabetes . 1979;;28:785-788.
Arias P, Kerner W, de la Fuente A, Pfeiffer EF. Abnormal growth hormone levels in insulin-dependent diabetic patients under continuous subcutaneous insulin infusion and intensified conventional treatment . Acta Endocrinol. 1984;;107:250-255.
Osterby R, Seyer-Hansen K, Gundersen HJG, Lundbaek K. Growth hormone enhances basement membrane thickening in experimental diabetes: a preliminary report . Diabetologia . 1978;;15:487-489.
Navalesi R, Pilo A, Vigneri R. Growth hormone kinetics in diabetic patients . Diabetes . 1975;;24:317-327.
Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes . N Engl J Med. 1984;;310:810-815.
Cohen MP, Urdanivia ZE, Wu VY. Nonenzymatic glycosylation of glomerular basement membrane . Renal Physiol. 1981;;4:90-95.
Beisswenger PG, Spiro RG. Human glomerular basement membrane: chemical alterations in diabetes mellitus . Science . 1970;;168:596-598.
Kefalides NA. Biochemical properties of human glomerular basement membrane in normal and diabetic kidneys . Adv Metabol Disord. 1973;;2(
(suppl 2)
):167-177.
Rohrbach DH, Martin GR. Structure of basement membrane in normal and diabetic tissue . Ann NY Acad Sci. 1982;;401:203-211.
Brownlee M. Microvascular disease and related abnormalities: their relation to control of diabetes . In: Marble A, Krall LP, Bradley FR, Christlieb AR, Soeldner JS, eds. Joslin's Diabetes Mellitus . 12th ed. Philadelphia, Pa: Lea & Febiger; 1985;:185-216.
Abouna GM et al. Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients . Lancet . 1983;;2:1274-1276.
Raskin P, Pietri AO, Unger R, Shannon WA. The effect of diabetic control on the width of skeletal-muscle capillary basement membrane in patients with type I diabetes mellitus . N Engl J Med. 1983;;309:1546-1550.
Camerini-Davalos RA et al: Drug-induced reversal of early diabetic microangiopathy . N Engl J Med. 1983;;309:1551-1556.
Mecklenburg RS, Benson EA, Benson JW, et al. Acute complications associated with insulin infusion pump therapy: report of experience with 161 patients . JAMA. 1984;;252:3265-3269.
Bell DSH, Ackerson C, Cutter G, Clements RS. Factors associated with discontinuation of continuous subcutaneous insulin infusion . Am J Med Sci. 1988;;295:23-28.
Teutsch SM, Herman WH, Dwyer DM, Lane JM. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps . N Engl J Med. 1984;;310:361-368.
Tanner MH, Liljenquist JE. Toxic shock syndrome from Staphylococcus aureus infection at insulin pump infusion sites . JAMA. 1988;;259:394-395.
Chantelau E, Lange G, Sonnenberg GE, Berger M. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment . Diabetes Care. 1987;;10:478-481.
Rivera-Alsina ME, Willis S. Needle and catheter colonization in pregnant diabetic patients using the continuous subcutaneous insulin infusion pump . Diabetes Care. 1984;;7:75-76.
Hazards of intensive insulin therapy . In: Shade DS, Santiago JV, Skyler JS, Rizza RA. Intensive Insulin Therapy . Amsterdam, the Netherlands: Medical Examination Publishing Co Inc; 1983;:287-301.
Nguyen TV, Burnett JW. Local skin reaction caused by the plastic catheter tubing of the continuous subcutaneous insulin infusion system . Cutis . 1988;;41:355-356.
Boom BW, Van Driel LMJ. Allergic contact dermatitis to epoxy resin in infusion sets of an insulin pump . Contact Dermatitis . 1985;;12:280.
Chantelau E, Lange G, Gasthaus M, Boxberger M, Berger M. Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy . Diabetes Care . 1987;;10:348-351.
Sartorius EA. Medical plastics and insulin-pump treatment . Diabetes Care. 1988;;11:370-371.
Problems associated with insulin-infusion devices . In: Shade DS, Santiago JV, Skyler JS, Rizza RA. Intensive Insulin Therapy . Amsterdam, the Netherlands: Medical Examination Publishing Co Inc; 1983;:302-313.
Centers for Disease Control. Deaths among patients using continuous subcutaneous insulin infusion pumps—United States, 1982 . MMWR. 1982;;31:80-87, 625-626.
Mecklenberg RS, Guinn TS, Sannar CA, Blumenstein BA. Malfunction of continuous subcutaneous insulin infusion systems: a one year prospective study of 127 patients . Diabetes Care . 1986;;9:351-355.
Peden NR, Braaten JT, McKendry JBR. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion . Diabetes Care . 1984;;7:1-5.
Bending JJ, Pickup JC. Complications of insulin infusion pump therapy . JAMA. 1985;;253:2644-2645.
Diabetes Control and Complications Trial (DCCT): results of feasibility study . Diabetes Care . 1987;;10:1-19.
Education for continuous subcutaneous insulin infusion pump users . Diabetes Educ. 1986;;13:10.
Nathan DM. Modern management of insulin-dependent diabetes mellitus . Med Clin North Am. 1989;;72:1365-1378.
Bergman M, Ravikumar S, Auerhahn C, Delsavio N, Savino J, Felig P. Insulin pump therapy improves blood glucose control during hyperalimentation . Arch Intern Med. 1984;;144:2013-2015.
Health Information for International Travel . Atlanta, Ga: Centers for Disease Control; 1988;. Dept of Health and Human Services publication (CDC) 88-8280.
Dupont HL, Ericsson CD, Johnson PC. Chemotherapy and chemoprophylaxis of travelers' diarrhea . Ann Intern Med. 1985;;102:260-261.
Dupont HL, Sullivan P, Evans DG, et al. Prevention of traveler's diarrhea (emporiatric enteritis) . JAMA. 1980;;243:237-241.
DuPont HL, Ericsson CD, Johnson PC, Bitsura JAM, DuPont MW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate . JAMA. 1987;;257:1347-1350.
Sack RB. Antimicrobial prophylaxis of travelers' diarrhea: a summary of studies using doxycycline or trimethoprim and sulphamethoxazole . Scand J Gastroenterol. 1983;;84(
(suppl)
):111-117.
Ericsson CD, Johnson PC, Dupont HL, Morgan DR, Bitsura JA, Cabada J. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea . Ann Intern Med. 1987;;106:216-220.
Travelers'diarrhea . JAMA . 1985;;253:2700-2704. Consensus Conference.